Bayer Launches Cell and Gene Therapy Platform
December 02 2020 - 2:41AM
Dow Jones News
By Olivia Bugault
Bayer AG said Wednesday that it has launched a cell and gene
therapy platform within its pharmaceutical division in order to
speed up innovation.
"The role of Bayer's cell and gene therapy platform is to steer
strategically, ensuring the different parts of the organization
complement each other and combining the best in Biotech and Pharma
know-how," the German chemicals and pharmaceutical conglomerate
said.
The platform will complement Bayer's existing pipeline of cell
and gene therapy products that comprises five assets and over
fifteen preclinical candidates, the company said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
December 02, 2020 03:26 ET (08:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Apr 2024 to May 2024
Bayer (TG:BAYN)
Historical Stock Chart
From May 2023 to May 2024